Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

Pinealon vs Cardiogen

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Pinealon and Cardiogen share the khavinson class and carry roughly equivalent evidence (Russian Research / Russian Research). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Pinealon

Russian Research

Cardiogen

Russian Research

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Shared safety considerations

Both compounds share these reported concerns: limited western evidence. Open each peptide page for the full risk paragraph and source citations.

Side-by-side

Pinealon Cardiogen
Class Khavinson short peptide bioregulator Khavinson short peptide bioregulator
Drug class Cognitive Tissue Repair
Mechanism DNA-binding peptide; modulates neuronal gene expression Tissue-specific gene expression modulation in cardiomyocytes
Route Oral / SC Oral
Half-life Short (minutes) Short (minutes)
Dosage (research) Oral capsule 1-2x daily Oral capsule 1-2x daily
Evidence tier Russian Research Russian Research
Research depth 25 indexed (PubMed 14 · CT 0 · EPMC 11) 11 indexed (PubMed 10 · CT 1 · EPMC 0)
Availability Research Research
Reported risks Limited Western evidence Limited Western evidence; no regulatory approval

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Pinealon or Cardiogen?

Pinealon and Cardiogen share the khavinson class and carry roughly equivalent evidence (Russian Research / Russian Research). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.

What is the difference between Pinealon and Cardiogen?

Pinealon is classed as Khavinson short peptide bioregulator; Cardiogen is classed as Khavinson short peptide bioregulator. Reported mechanism: Pinealon, DNA-binding peptide; modulates neuronal gene expression; Cardiogen, Tissue-specific gene expression modulation in cardiomyocytes. Reported half-life: Pinealon, Short (minutes); Cardiogen, Short (minutes). Routes in published studies: Pinealon, Oral / SC; Cardiogen, Oral.

Which has stronger evidence, Pinealon or Cardiogen?

Pinealon and Cardiogen sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Pinealon is graded Russian Research, with 2 cited sources on its reference page and 25 indexed studies. Cardiogen is graded Russian Research, with 2 cited sources on its reference page and 11 indexed studies.

Which is more accessible, Pinealon or Cardiogen?

Neither Pinealon nor Cardiogen is an FDA-approved drug. Catalog status: Pinealon, Research; Cardiogen, Research.

Are Pinealon and Cardiogen ever combined?

Pinealon and Cardiogen appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…